Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

TCGA-LQ-A4E4-01A-11R-A266-07

· B

e5c50559-04c5-52b0-8786-4497a6ca0d67

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
B
subtype
B
overall_survival_months
28
os_event
false

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.170
  • E2F_TARGETS+0.130
  • MYC_TARGETS_V2+0.120
  • MITOTIC_SPINDLE+0.060
  • DNA_REPAIR+0.030
  • FATTY_ACID_METABOLISM+0.000
  • PEROXISOME-0.010
  • ADIPOGENESIS-0.020
  • SPERMATOGENESIS-0.020
  • ESTROGEN_RESPONSE_LATE-0.040

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.580
  • INTERFERON_GAMMA_RESPONSE-0.580
  • TNFA_SIGNALING_VIA_NFKB-0.580
  • INTERFERON_ALPHA_RESPONSE-0.520
  • INFLAMMATORY_RESPONSE-0.510
  • IL6_JAK_STAT3_SIGNALING-0.490
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
  • APOPTOSIS-0.410
  • COMPLEMENT-0.410
  • IL2_STAT5_SIGNALING-0.380

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SRR1385036
brain-umap@2
GTEX0.929
2BS_A87NPZAP
brain-umap@2
medulloblastoma0.926
3SRR8518343
breast-umap@18
E0.919
4SRR1441224
brain-umap@2
GTEX0.919
5BS_D0RDN4K5
brain-umap@2
Embryonal tumors0.918
6SRR1357413
brain-umap@2
GTEX0.917
7SRR1399904
brain-umap@2
GTEX0.916
8SRR807657
brain-umap@2
GTEX0.916
9SRR1472621
brain-umap@2
GTEX0.915
10SRR8518194
breast-umap@18
D0.915

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 5 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.170Inavolisib— uncovered
E2F_TARGETS0.130Inavolisib— uncovered
MYC_TARGETS_V20.120Idelalisib— uncovered
MITOTIC_SPINDLE0.060Inavolisib— uncovered
DNA_REPAIR0.030Idelalisib— uncovered